INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

被引：0
作者：
Baquerizo, Angeles [1 ,2 ]
Vavinskaya, Vera [3 ]
Rojas, Angela [4 ]
Mhoyan, Anna [5 ]
Romero-Gomez, Manuel [6 ]
Sher, Linda [7 ]
Madani, Bahar [2 ]
Fisher, Jonathan [1 ]
Schaffer, Randolph [1 ]
Frenette, Catherine T. [8 ]
Marsh, Christopher [9 ]
机构：
[1] Scripps Hlth, Surg, La Jolla, CA USA
[2] Scripps Clin, La Jolla, CA 92037 USA
[3] UCSD, Pathol, La Jolla, CA USA
[4] Virgen Del Rocio Univ Hosp, Hepatol, Seville, Spain
[5] Kaiser, Pathol, San Diego, CA USA
[6] Virgen Del Rocio Univ Hosp, Seville, Spain
[7] USC, Los Angeles, CA USA
[8] Scripps Hlth, Scripps Clin, La Jolla, CA USA
[9] Scripps Hlth, La Jolla, CA USA
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
321
引用
收藏
页码：206A / 206A
页数：1
相关论文
共 50 条
  • [31] PD-L1 expression in hepatocellular carcinoma
    Kanda, Hiroaki
    Mahmut, Yasin
    Shigematsu, Yasuyuki
    Sugiura, Yoshiya
    Yamamoto, Noriko
    Ishikawa, Yuichi
    CANCER SCIENCE, 2018, 109 : 1123 - 1123
  • [32] ABCB5 knockdown suppresses tumor-intrinsic expression of immune checkpoint regulators PD-1 and PD-L1 in hepatocellular carcinoma (HCC)
    Yeung, Chun Philip
    Wilson, Brian J.
    Sasamoto, Yuzuru
    Waaga-Gasser, Ana Maria
    Karpova, Svetlana
    Guo, Qin
    Frank, Natasha Y.
    Frank, Markus H.
    CANCER RESEARCH, 2023, 83 (07)
  • [33] N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
    Bar Kaufman
    Muhammad Abu-Ahmad
    Olga Radinsky
    Eman Gharra
    Tal Manko
    Baisali Bhattacharya
    Daniela Gologan
    Nofar Erlichman
    Tsipi Meshel
    Yoav Nuta
    Tomer Cooks
    Moshe Elkabets
    Adit Ben-Baruch
    Angel Porgador
    Molecular Cancer, 24 (1)
  • [34] Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma
    Wei, Hangzhi
    Wu, Fahong
    Mao, Yudong
    Zhang, Youcheng
    Leng, Guangxian
    Wang, Jia
    Zhang, Wei
    Wang, Tianwei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (04) : 331 - 345
  • [35] Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
    Wang, Jiting
    Li, Jun
    Tang, Guiju
    Tian, Yuan
    Su, Song
    Li, Yaling
    ONCOLOGY LETTERS, 2021, 21 (04) : 1 - 8
  • [36] The expression level and prognostic value of PD-L1 and PD-1 in cervical carcinoma patients
    Bao, Yongxing
    Zhang, Songan
    Niyazi, Huerdidan
    Tuluwengjiang, Gulixian
    Zhang, Lei
    Zhang, Yang
    Su, Weipeng
    CANCER RESEARCH, 2017, 77
  • [37] Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents
    Kamal, Monica A.
    Badary, Hedy A.
    Omran, Dalia
    Shousha, Hend I.
    Abdelaziz, Ashraf O.
    El Tayebi, Hend M.
    Mandour, Yasmine M.
    ACS OMEGA, 2023, 8 (37): : 33242 - 33254
  • [38] Expression and prognostic value of PD-1 and PD-L1 in colorectal carcinoma
    Aouadi, R.
    Helal, I.
    Khanchel, F.
    Hedhli, R.
    Ben Brahim, E.
    Jouini, R.
    Debbiche, A. Chadli
    VIRCHOWS ARCHIV, 2024, 485 : S151 - S152
  • [39] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
    Caccese, Mario
    Indraccolo, Stefano
    Zagonel, Vittorina
    Lombardi, Giuseppe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
  • [40] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
    Maslanka, A.
    Kitel, R.
    Konopka, J.
    Skalniak, L.
    FEBS OPEN BIO, 2024, 14 : 329 - 330
12345